213 related articles for article (PubMed ID: 18799100)
21. [B cell depletion therapy using anti-CD20 antibodies in rheumatoid arthritis].
Yukawa N; Mimori T
Clin Calcium; 2007 Apr; 17(4):569-76. PubMed ID: 17404487
[TBL] [Abstract][Full Text] [Related]
22. Induction of long-term B-cell depletion in refractory rheumatoid arthritis patients preferentially affects autoreactive more than protective humoral immunity.
Teng YK; Wheater G; Hogan VE; Stocks P; Levarht EW; Huizinga TW; Toes RE; van Laar JM
Arthritis Res Ther; 2012 Mar; 14(2):R57. PubMed ID: 22409963
[TBL] [Abstract][Full Text] [Related]
23. Expression of interferon beta in synovial tissue from patients with rheumatoid arthritis: comparison with patients with osteoarthritis and reactive arthritis.
van Holten J; Smeets TJ; Blankert P; Tak PP
Ann Rheum Dis; 2005 Dec; 64(12):1780-2. PubMed ID: 15878901
[TBL] [Abstract][Full Text] [Related]
24. B-cell: a logical target for treatment of rheumatoid arthritis.
Youinou P; Jamin C; Saraux A
Clin Exp Rheumatol; 2007; 25(2):318-28. PubMed ID: 17543163
[TBL] [Abstract][Full Text] [Related]
25. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis.
Leandro MJ; Cambridge G; Ehrenstein MR; Edwards JC
Arthritis Rheum; 2006 Feb; 54(2):613-20. PubMed ID: 16447239
[TBL] [Abstract][Full Text] [Related]
26. [Targeting CD20 in rheumatoid arthritis].
Saito K; Tanaka Y
Nihon Rinsho; 2007 Jul; 65(7):1243-9. PubMed ID: 17642239
[TBL] [Abstract][Full Text] [Related]
27. B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience.
Shaw T; Quan J; Totoritis MC
Ann Rheum Dis; 2003 Nov; 62 Suppl 2(Suppl 2):ii55-9. PubMed ID: 14532151
[No Abstract] [Full Text] [Related]
28. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis.
Roll P; Palanichamy A; Kneitz C; Dorner T; Tony HP
Arthritis Rheum; 2006 Aug; 54(8):2377-86. PubMed ID: 16869000
[TBL] [Abstract][Full Text] [Related]
29. Perspectives of ofatumumab as CD20 targeted therapy in rheumatoid arthritis and other autoimmune diseases.
Pers YM; Jorgensen C
Immunotherapy; 2016 Sep; 8(9):1091-6. PubMed ID: 27485081
[TBL] [Abstract][Full Text] [Related]
30. Longterm effects of rituximab on B cell counts and autoantibody production in rheumatoid arthritis: use of high-sensitivity flow cytometry for more sensitive assessment of B cell depletion.
Váncsa A; Szabó Z; Szamosi S; Bodnár N; Végh E; Gergely L; Szucs G; Szántó S; Szekanecz Z
J Rheumatol; 2013 May; 40(5):565-71. PubMed ID: 23547216
[TBL] [Abstract][Full Text] [Related]
31. Anti-CD20 monoclonal antibody in rheumatoid arthritis and systemic lupus erythematosus.
Goldblatt F; Isenberg DA
Handb Exp Pharmacol; 2008; (181):163-81. PubMed ID: 18071946
[TBL] [Abstract][Full Text] [Related]
32. Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment.
Higashida J; Wun T; Schmidt S; Naguwa SM; Tuscano JM
J Rheumatol; 2005 Nov; 32(11):2109-15. PubMed ID: 16265687
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells.
De Vita S; Zaja F; Sacco S; De Candia A; Fanin R; Ferraccioli G
Arthritis Rheum; 2002 Aug; 46(8):2029-33. PubMed ID: 12209504
[TBL] [Abstract][Full Text] [Related]
34. Detection, identification and in vivo treatment responsiveness of bone morphogenetic protein (BMP)-activated cell populations in the synovium of patients with rheumatoid arthritis.
Verschueren PC; Lories RJ; Daans M; Théate I; Durez P; Westhovens R; Luyten FP
Ann Rheum Dis; 2009 Jan; 68(1):117-23. PubMed ID: 18276742
[TBL] [Abstract][Full Text] [Related]
35. Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy.
Leandro MJ; Cooper N; Cambridge G; Ehrenstein MR; Edwards JC
Rheumatology (Oxford); 2007 Jan; 46(1):29-36. PubMed ID: 16735454
[TBL] [Abstract][Full Text] [Related]
36. Presence of hepatitis B virus in synovium and its clinical significance in rheumatoid arthritis.
Chen YL; Jing J; Mo YQ; Ma JD; Yang LJ; Chen LF; Zhang X; Yan T; Zheng DH; Pessler F; Dai L
Arthritis Res Ther; 2018 Jun; 20(1):130. PubMed ID: 29921328
[TBL] [Abstract][Full Text] [Related]
37. Long term treatment of rheumatoid arthritis with rituximab.
Caporali R; Caprioli M; Bobbio-Pallavicini F; Bugatti S; Montecucco C
Autoimmun Rev; 2009 Jun; 8(7):591-4. PubMed ID: 19393205
[TBL] [Abstract][Full Text] [Related]
38. The alternative CD20 transcript variant is not a surrogate marker for resistance to rituximab in patients with rheumatoid arthritis.
Gamonet C; Deschamps M; Marion S; Herbein G; Chiocchia G; Auger I; Saas P; Ferrand C; Toussirot E
Rheumatology (Oxford); 2015 Sep; 54(9):1744-5. PubMed ID: 26117335
[No Abstract] [Full Text] [Related]
39. B cell-directed therapy in rheumatoid arthritis--clinical experience.
Panayi GS
J Rheumatol Suppl; 2005 Feb; 73():19-24; discussion 29-30. PubMed ID: 15693112
[TBL] [Abstract][Full Text] [Related]
40. Response to rituximab and timeframe to relapse in rheumatoid arthritis patients: association with B-cell markers.
Pyrpasopoulou A; Douma S; Triantafyllou A; Simoulidou E; Samara M; Parapanisiou E; Aslanidis S
Mol Diagn Ther; 2010 Feb; 14(1):43-8. PubMed ID: 20121289
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
